Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
Thalidomide Shows Potential for Treating Brain Vascular Malformations
Researchers at Capital Medical University demonstrate that thalidomide can stabilize rare central nervous system vascular malformations (CNS-AVMs).
Atopic Dermatitis Topical Treatments: DB-006 Outperforms Rivals
Derm-Biome's novel topical small molecule DB-006 demonstrates superior preclinical efficacy, reducing itch, inflammation, and S. aureus bacteria.
Mesothelioma Targeted Therapy: Amivantamab Dual Targeting Preclinical Data
A new study explores amivantamab, a dual EGFR and MET bispecific antibody, as an innovative targeted therapy option for diffuse pleural mesothelioma.
FDA Priority Review Voucher: Denali Sells Regulatory Pass for $195M
Denali Therapeutics sells its priority review voucher for $195 million to advance its blood-brain barrier neurodegenerative pipeline development.
Multiple Myeloma New Treatment: Sarclisa Wins MHRA Approval for OBI Use
Sanofi’s Sarclisa (isatuximab) achieves UK MHRA approval as the first multiple myeloma anti-cancer therapy administered via on-body injector.
Global Clinical Trials: Avance Clinical Expands APAC & China CRO Operations
Announced at BIO 2026, global Contract Research Organization Avance Clinical expands its biotech trial footprint into Singapore, Malaysia, and China.
Hemophilia B Cell Therapy: Be Bio Shuts Down Lead BE-101 Trial
Be Biopharma terminates its Phase 1/2 clinical study for hemophilia B cell therapy BE-101, reflecting strategic industry shifts away from gene programs.
Preclinical Immunology Assets: Biogen Inks $1B RayThera Acquisition
Preclinical Immunology Assets: Biogen Inks $1B RayThera Acquisition
Large B-Cell Lymphoma Clinical Trials: FDA Reviews Mosunetuzumab sBLA
The FDA accepts a supplemental biologics application for subcutaneous mosunetuzumab plus polatuzumab vedotin for relapsed/refractory LBCL.
Post GLP-1 Weight Management: Preclinical Success for Coca Leaf Extract
Magdalena Biosciences reports positive preclinical results showing a novel botanical coca leaf extract prevents weight gain following GLP-1 cessation.
Sepsis Treatment Options: New Preclinical Model Evaluates Vitamin C
Researchers at Monash University develop a highly accurate preclinical sepsis model to test sodium ascorbate, a pH-balanced form of Vitamin C.
Qihan Biotech's Universal CAR-T Therapy Wins FDA Breakthrough Status
Qihan Biotech's universal dual-target CAR-T therapy, QT-019B, secures FDA Breakthrough Therapy and RMAT designations, achieving a milestone "triple crown".
1
2
3
4
5
6
7
